Blood Test Predicts Rectal Cancer Return Before Scans Can

For people finishing rectal cancer treatment, the hardest question isn't about the therapy itself. It's whether microscopic cancer cells are still hiding somewhere in the body, invisible to scans and exams.

Researchers just found a powerful new answer. A blood test measuring circulating tumor DNA (ctDNA) predicted which patients would see their cancer return with remarkable accuracy, often months before traditional methods could detect anything wrong.

The study followed 220 people with stage II or III rectal cancer across multiple medical centers between 2018 and 2024. After completing chemotherapy and radiation, some patients had surgery while others chose a watch-and-wait approach, skipping immediate surgery in favor of careful monitoring.

Here's where the blood test made all the difference. When cancer cells die, they release tiny DNA fragments into the bloodstream. The test searches for these fragments after treatment ends.

The results were striking. Nearly every watch-and-wait patient whose blood showed detectable ctDNA eventually experienced cancer recurrence. Meanwhile, only a small percentage of patients with undetectable ctDNA saw their cancer return.

Even more revealing, the blood test often contradicted what doctors saw on scans. Many patients appeared completely cancer-free on MRIs and endoscopies, yet their blood told a different story. Those with detectable ctDNA faced much higher recurrence rates despite looking healthy on traditional tests.

The same pattern held after surgery. Patients with detectable ctDNA weeks after their operation had dramatically higher chances of recurrence than those whose blood came back clean.

The Bright Side

This isn't just about better prediction. It's about giving people real choices based on their individual situation.

Patients with no detectable ctDNA might eventually avoid unnecessary follow-up treatments or invasive testing. Those with persistent ctDNA could benefit from closer monitoring, additional therapies, or clinical trials designed to eliminate remaining cancer cells before they grow.

The blood test also bought something precious: time. When ctDNA levels rose during routine monitoring, it happened months before recurrence showed up on standard tests. That early warning could give doctors and patients more options before the cancer advances.

Researchers stress that treatment decisions can't be based on ctDNA alone yet. This was a retrospective study, meaning scientists looked backward at patient data rather than testing the approach in real time. Larger prospective trials are needed to confirm these findings.

But the potential is undeniable. Instead of treating every patient identically after therapy, doctors could eventually personalize follow-up care based on each person's ctDNA results. Some patients might need more aggressive monitoring. Others might safely skip treatments that would have caused unnecessary side effects.

The test represents a shift from one-size-fits-all cancer care to precision medicine that sees each patient as an individual with unique risks and needs.